AmerisourceBergen Launches Clinical Trial Navigator to Bolster Equitable and Accessible Community-Based Research Opportunities Nationwide
Clinical Trial Navigator matches biopharma companies with independently-owned specialty physician practices to increase recruitment opportunities and expand pool of potential enrollees for trials
Carol Riley, RN, BSN, Practice Administrator at St. Louis Cancer Care, LLP said, “Clinical trials present the opportunity for patients to access cutting-edge therapies and offer hope for patients who may have exhausted all available treatment options. However, there have been limits to accessing this research for patients at my community-based practice. Programs that enhance and streamline recruitment efforts for community practices are much needed, and having the ability to connect more patients with active trials will be a huge win.”
About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies, and providers, we create unparalleled access, efficiency, and reliability for human and animal health. Our 42,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at https://amerisourcebergen.com/.
“Historically, it has been difficult for biopharmaceutical companies to have a consolidated and holistic view of independent specialty practices and their patient populations, and, as a result, clinical trial enrollment and logistics in these care settings have been complex and difficult to execute,” said Jennifer Sherak, SVP & President of Specialty Physician Services, AmerisourceBergen. “With Clinical Trial Navigator, we want to break down these barriers for biopharma companies, bring more clinical trials into communities nationwide, help broaden the patient populations being considered for trials, and ultimately advance accrual time and bring therapies to market faster. By creating this connectivity, we also hope to generate more equitable and accessible trial opportunities for underrepresented racial and ethnic groups, rural patients, older adults, and other underserved communities.”
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.